Table 1.

Primers Used for Conventional PCR and Sanger Sequencing

Genes	Exon	Primer name	Sequence (5′-3′)	Amplicon size (bp)	Ta (°C)
Primers for Assessment of DNA Quality by Conventional Multiplex PCR
RAG1	E2	Forward	5′-TGTTGACTCGATCCACCCCA-3′	200	60
Reverse	5′-TGAGCTGCAAGTTTGGCTGAA-3′
PLZF	E1	Forward	5′-TGCGATGTGGTCATCATGGTG-3′	300	60
Reverse	5′-CGTGTCATTGTCGTCTGAGGC-3′
AF4	E11	Forward	5′-CCGCAGCAAGCAACGAACC-3′	400	60
Reverse	5′-GCTTTCCTCTGGCGGCTCC-3′
AF4	E3	Forward	5′-GGAGCAGCATTCCATCCAGC-3′	600	60
Reverse	5′-CATCCATGGGCCGGACATAA-3′
Primers for Investigation of Mutations in Oncogenes and Tumor Suppressor Genes Involved in DLBCL by PCR and Sanger Sequencing
CARD11	E5-1	Forward	5′-GTGCCCCCTCTCCACAGT-3′	200	62
Reverse	5′-AGTACCGCTCCTGGAAGGTT-3′
E5-2	Forward	5′-GAAGAAGCAGATGACGCTGA-3′	235	62
Reverse	5′-GTCACCCTGGCGGAGTAG-3′
E6	Forward	5′-CACCCTTGGGGTATTTCAGA-3′	210	59
Reverse	5′-CAGGCCCTCACCTGGATG-3′
E7	Forward	5′-CCTGACCCTCTGAAACCTCCT-3′	204	62
Reverse	5′-GCGATCCCCACTCCCAC-3′
E8	Forward	5′-TCGATGCGCATATTGATTTC-3′	181	62
Reverse	5′-CTGCAGGTGGTGCCTGTA-3′
E9	Forward	5′-CCCAAAGCAGCCTTCGTC-3′	234	62
Reverse	5′-cCTGGTCCAGGTTGTTGCTGTCC-3′
MYD88	E1-1	Forward	5′-CTCGGGGCTCCAGATTGTA-3′	327	58
Reverse	5′-GCCGGATCTCCAAGTACTCA-3′
E1-2	Forward	5′-GCTGCTCTCAACATGCGAGT-3′	317	62
Reverse	5′-GGAAAGTCAGCCTCCTCACC-3′
E2	Forward	5′-CTGGATCCTGACTGTGGGTAA-3′	281	62
Reverse	5′-GCTTCAAACACCCATGCTCT-3′
E3	Forward	5′-TCTGACCACCACCCTTGTG-3′	264	62
Reverse	5′-CAGGGCAGGGCTTCATGC-3′
E4	Forward	5′-GGCCCTTCCTGAAGCTATTC-3′	270	62
Reverse	5′-TGGTACTGCATCCACAGTCC-3′
E5	Forward	5′-GTTGAAGACTGGGCTTGTCC-3′	292	59
Reverse	5′-AGGAGGCAGGGCAGAAGTA-3′
CD79A	E5	Forward	5′-ATGAAGTGAGTGAAGGGTGGG-3′	326	58
Reverse	5′-AGAATGTCCCAGGGAAGTGAG-3′
CD79B	E5	Forward	5′-TAGGTGGCTGTCTGGTCAATG-3′	306	58
Reverse	5′-TGTTCTTGCAGAATGCACCTC-3′
E6	Forward	5′-CTGGAGACAAATGGCAGCTC-3′	362	58
Reverse	5′-CACCTACGAGGTAAGGAGAGGG-3′
PRDM1	E1	Forward	5′-GGAGAATGTGGACTGGGTAG-3′	220	55
Reverse	5′-TAAGTGCACTAAAGCAGAAGC-3′
E2-1	Forward	5′-TGTATTAGTCATAGCCTCTCA-3′	367	55
Reverse	5′-CTCTTCAAACTCAGCCTCTGT-3′
E2-2	Forward	5′-TGTGAGGTTTCAGGGATTGGCAGA-3′	261	55
Reverse	5′-AGGTCCCCAATCTTCTTGTC-3′
E3	Forward	5′-TTGTATTACTACTTGACAGTCC-3′	258	55
Reverse	5′-TTCCTAACATTTAATGGGTCTG-3′
E4-1	Forward	5′-GTTTATTCTGAGAGGTGCTGG-3′	253	55
Reverse	5′-CAAGAAGTTCCTGGTTGGCA-3′
E4-2	Forward	5′-ATGTGAATCCAGCACACTCTC-3′	289	55
Reverse	5′-TCCAACACATGACAAAGCCGT-3′
E5-1	Forward	5′-TTGCTTCAGTTCTCTCTAGCC-3′	243	55
Reverse	5′-TTCTAAAGTCATCGAGGTCC-3′
E5-2	Forward	5′-TCCTAAAATTGGACTCCAACC-3′	294	55
Reverse	5′-TGGAGCTCTTGAGGCTTTGGT-3′
	E5-3	Forward	5′-AGACTTTTTGAAAGCTTCC-3′	300	55
Reverse	5′-TTGTACGAGGGGATGAAAGCTG-3′
E5-4	Forward	5′-TACGCTTACTTGAACGCGTC-3′	278	55
Reverse	5′-AGAGAAGTGGGGTTGAGCAT-3′
E5-5	Forward	5′-ATCAACAACTTTGGCCTCTTC-3′	296	55
Reverse	5′-TTGGGCTGCACCACATGTTCT-3′
E5-6	Forward	5′-ATGAAGGACAAGGCCTGTAG-3′	314	55
Reverse	5′-CAAACACAAGCATGCACTCAC-3′
E6	Forward	5′-AACACTTGAGTCTTGGAGCAG-3′	267	55
Reverse	5′-GTGACTCACAGACATTTTCTA-3′
E7-1	Forward	5′-TTGGCAACTCTTAATCTTCTGG-3′	284	55
Reverse	5′-TCAGGTGAACCTTGAGGCTACAG-3′
E7-2	Forward	5′-CCAAGTTCACCCAGTTTGTG-3′	297	55
Reverse	5′-TTCTGACCACGGCCAGAATTTC-3′
E7-3	Forward	5′-TGACATCAGTGACAATGCTGAC-3′	313	55
Reverse	5′-ACTCACCAAGTCATAACTTA-3′
TP53	E5	Forward	5′-CACTTGTGCCCTGACTTTCA-3′	267	64
Reverse	5′-AACCAGCCCTGTCGTCTCT-3′
E6	Forward	5′-GAGAGACGACAGGGCTGGT-3′	231	62
Reverse	5′-CACTGACAACCACCCTTAACC-3′
E7	Forward	5′-CCTGCTTGCCACAGGTCT-3′	295	62
Reverse	5′-GTGATGAGAGGTGGATGGGTAG-3′
E8	Forward	5′-GGACAGGTAGGACCTGATTTCC-3′	257	64
Reverse	5′-TGAATCTGAGGCATAACTGCAC-3′
E9	Forward	5′-GACCAAGGGTGCAGTTATGC-3′	277	62
Reverse	5′-ACCAGGAGCCATTGTCTTTG-3′
E10	Forward	5′-AACTTGAACCATCTTTTAACTCAGG-3′	242	62
Reverse	5′-GAATCCTATGGCTTTCCAACCT-3′
TNFAIP3	E2a	Forward	5′-CTGCAGGCAGCTATAGAGGAG-3′	272	58
Reverse	5′-CGAAACTGAGGACAAAACTGG-3′
E2b	Forward	5′-GCAATATGCGGAAAGCTGTG-3′	300	58
Reverse	5′-GCTATCACCCAGGCAAAAGA-3′
E3	Forward	5′-TTGCTGGGTCTTACATGCAG-3′	378	58
Reverse	5′-GCTTCGCTTAGCCAAATTCA-3′
E4	Forward	5′-GGGAGTACAGGATACATTCAAGC-3′	251	58
Reverse	5′-AAGGCATAAGGCTGAAAGCA-3′
E5	Forward	5′-ACCTAAGGGCCTCATTTTCC-3′	275	58
Reverse	5′-GCAAAAAGGAAAACCCTGATG-3′
E6	Forward	5′-TGAGATCTACTTACCTATGGCCTTG-3′	315	58
Reverse	5′-TCAGGTGGCTGAGGTTAAAGA-3′
E7a	Forward	5′-ACAGGCCTGCATTTCAGTG-3′	282	58
Reverse	5′-GGAAGGTTCCATGGGATTC-3′
E7b	Forward	5′-GCAGGAAAACAGCGAGCA-3′	272	58
Reverse	5′-CCAAGGGCTCATAGGCTTCT-3′
E7c	Forward	5′-ACTCCCAAAGCTGAACTCCA-3′	304	58
Reverse	5′-GGGATCCAAGTGCCTTGT-3′
E7d	Forward	5′-ACTGCCATGAAGTGCAGGAG-3′	279	58
Reverse	5′-ATCTGACTTGGAACGCTGGT-3′
E7e	Forward	5′-TGCAGTACTTGCTTCAAAAGGA-3′	313	58
Reverse	5′-CCACTTCACTCACGTTTGTTTT-3′
E8	Forward	5′-GGGGTGACCCCTATGTGGTACT-3′	293	58
Reverse	5′-CCAGTTGCTCTTCTGTCCTTTT-3′
E9a	Forward	5′-GTGCTCTCCCTAAGAAATGTGAG-3′	205	58
Reverse	5′-CTGGTTGGGATGCTGACACT-3′
E9b	Forward	5′-CTCTGCATGGAGTGTCAGCAT-3′	257	58
Reverse	5′-GGGTTCAGAGGATAGCACCA-3′

DLBCL, diffuse large B-cell lymphoma; E, exon.